• Vaccine Name: rMeV- SCD
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0004713
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• FCY1 gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Lange et al., 2013)
  • Detailed Gene Information: Click Here.
• SPBC17D11.03c hypothetical protein gene engineering:
  • Type: Recombinant protein preparation
  • Description: (Lange et al., 2013)
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001056
• Preparation: A measles vaccine virus (MeV) vector expressing super cytosine deaminase (SCD), a fusion protein of yeast cytosine deaminase and uracil phosphoribosyltransferase (Lange et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Vaccination Protocol: When tumors reached a volume of about 100 mm^3, mice were randomized into four treatment groups: control, control+5-FC, MeV, and MeV+5-FC. Mice received intratumoral injections of MeV (either 1×10^6 pfu/dose of MeV P-SCD for TFK-1 or 2×10^6 pfu/dose of MeV ld-SCD for HuCCT1 in 100 μl Opti-MEM) or Opti-MEM alone once daily on days 0–4. Mice randomized to the 5-FC groups received daily intraperitoneal injections of 5-FC (500 mg/kg body weight/dose in PBS) on days 5–11 (Lange et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: FK-1 cells (1×10^7 cells each in 100 μl PBS) were injected subcutaneously into the right flank of 4–6-week-old female CanN.Cg-Foxn1nu/Crl mice . In a second experiment, HuCCT1 cells were implanted subcutaneously in Hsd:Atymic Nude-Foxn1nu mice (Lange et al., 2013).
• Efficacy: In vivo, intratumoral application of SCD-armed MeV together with a systemic 5-FC treatment showed a significant reduction in tumor size in a TFK-1 xenograft mouse model when compared with virus-only treatment. In a second animal experiment employing a HuCCT1 xenograft tumor model, an enhanced SCD-armed MeV vector, in which the SCD transgene was expressed from a different genomic position, led not only to reduced tumor volumes, but also to a significant survival benefit (Lange et al., 2013).